Title: Etanercept
CAS Registry Number: 185243-69-0
CAS Name: 1-235-Tumor necrosis factor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human g1-chain Fc fragment)
Additional Names: human tumor necrosis factor receptor p75 Fc fusion protein; TNFR:Fc
Trademarks: Enbrel (Wyeth)
Literature References: Recombinant protein consisting of the human soluble TNF receptor p75 linked to the Fc portion of human immunoglobulin G1. Dimerizes via the cysteine residues in the Fc fragment to form an immunoglobulin-like structure. Inhibits the biological effects of tumor necrosis factor, q.v. Description of prepn and medicinal use: C. A. Smith, C. A. Jacobs, WO 9406476; eidem, US 5605690 (1994, 1997 both to Immunex). Clinical pharmacokinetics: H. Lee et al., Clin. Pharmacol. Ther. 73, 348 (2003). Clinical trial as monotherapy in plaque psoriasis: C. L. Leonardi et al., N. Engl. J. Med. 349, 2014 (2003). Review of clinical experience in rheumatoid and psoriatic arthritis: B. Goffe, J. C. Cather, J. Am. Acad. Dermatol. 49, S105-S111 (2003); S. Nanda, J. M. Bathon, Expert Opin. Pharmacother. 5, 1175-1186 (2004).
Therap-Cat: Anti-inflammatory; antipsoriatic.
Keywords: Antipsoriatic; Anti-inflammatory (Biological Response Modifier).

Others monographs:
Calcium PhosphiteAmmonium Cerous SulfatePyronaridineEthyl Alcohol, Denatured
TriostinsAzaperoneOil of TansyPhenylmercuric Acetate
Penicillin VPuberulonic AcidQuinapyramineAllyl Cyanide
Okadaic AcidMercury MassCeric FluorideVioluric Acid
©2016 DrugLead US FDA&EMEA